Skip to content
Open access

Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile

Oct 2026 · Journal of Molecular Histology · Vol 57 · 0 citations · 40 references
Medicine

Abstract

This study investigated whether Retatrutide, a triple incretin agonist, attenuates early diabetes-associated renal injury in a streptozotocin-induced rat model, and whether any protective effect is mediated through modulation of inflammatory cytokines (IL-1β, TNF-α) and HIF-1α gene expression in kidney tissue. Male Sprague-Dawley rats were divided into four groups: control, STZ-induced diabetic, STZ plus Retatrutide, and Retatrutide alone. Diabetes was induced via a single intraperitoneal STZ injection; Retatrutide was administered subcutaneously for 21 days at a dose adapted from prior metabolic studies. Renal tissue underwent ELISA for interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α), quantitative real-time PCR for HIF-1α expression, and semi-quantitative histopathological scoring of cortical and medullary parameters including haemorrhage, tubular dilatation, inflammatory cell infiltration, tubular vacuolisation, interstitial fibrosis, and intraluminal debris. STZ-induced rats exhibited significantly elevated cortical and medullary histopathological scores and increased renal IL-1β levels relative to controls, confirming successful early injury induction. Retatrutide did not produce statistically significant histopathological protection, although STZ plus Retatrutide animals showed consistently lower damage scores than STZ-only animals, corresponding to large standardised effects (Cliff’s δ = 0.90 in the cortex and 0.85 in the medulla) that could not be confirmed under family-wise error correction. HIF-1α expression was highest in the untreated diabetic group and was significantly lower in Retatrutide-treated diabetic animals (S vs. SR, p = 0.020), whereas Retatrutide alone did not alter expression relative to controls. TNF-α did not differ significantly in any pairwise comparison; levels in Retatrutide-treated diabetic animals were nonetheless comparable to controls (g* = 0.03). Retatrutide selectively modulated HIF-1α transcriptional levels in the acute STZ model without statistically confirmed histopathological renoprotection, and without evidence of intrinsic renal toxicity. Because the acute STZ model reflects insulin-deficient rather than T2DM-like disease, the model itself is a critical limitation; chronic type 2 diabetes models, together with longer treatment durations and refined dosing regimens, are required to determine whether the observed early molecular effects translate into structural renal benefit. Model validity and inflammatory signature: Streptozotocin-induced diabetes produced a robust early diabetic kidney injury model, evidenced by significantly increased IL-1β levels and marked cortical and medullary histopathological damage in the diabetic group compared with controls. Histopathological protection by Retatrutide was not statistically confirmed: RET did not produce statistically significant histopathological protection under family-wise-corrected post hoc testing; however, STZ+RET animals showed consistently lower cortical and medullary scores than STZ animals, corresponding to large standardised effects (Cliff's δ = 0.90 and 0.85, respectively) whose confidence intervals excluded negligible differences. Retatrutide modulates hypoxia-related molecular responses: HIF-1α gene expression was highest in untreated diabetic kidneys and was significantly lower in diabetic animals treated with Retatrutide (S vs. SR, p = 0.020) - the contrast in which diabetic status is held constant. Retatrutide alone did not alter HIF-1α relative to controls (R vs. C, δ = −0.28), indicating that the effect emerges under diabetic conditions rather than reflecting generalised suppression, and that it precedes clear structural recovery. Inflammatory cytokines show partial, power-limited signals: While IL-1β was significantly increased in the diabetic group, renal TNF-α in Retatrutide-treated diabetic animals was indistinguishable from that of controls (SR vs. C, g* = 0.03) despite a large standardised difference from untreated diabetic animals (S vs. SR, g* = 1.60), a contrast that did not reach significance under the conservative Games–Howell correction at the available sample sizes. This pattern is compatible with an anti-inflammatory trend that the present design was underpowered to confirm. Renal safety signal and translational implication: Retatrutide alone did not induce renal toxicity, as total cortical and medullary scores and subparameter scores in the Retatrutide-only group were comparable to controls, aligning with clinical data suggesting a favourable renal safety profile of incretin-based therapies and supporting further evaluation in chronic, T2DM-like models with longer treatment and functional readouts. Model validity and inflammatory signature: Streptozotocin-induced diabetes produced a robust early diabetic kidney injury model, evidenced by significantly increased IL-1β levels and marked cortical and medullary histopathological damage in the diabetic group compared with controls. Histopathological protection by Retatrutide was not statistically confirmed: RET did not produce statistically significant histopathological protection under family-wise-corrected post hoc testing; however, STZ+RET animals showed consistently lower cortical and medullary scores than STZ animals, corresponding to large standardised effects (Cliff's δ = 0.90 and 0.85, respectively) whose confidence intervals excluded negligible differences. Retatrutide modulates hypoxia-related molecular responses: HIF-1α gene expression was highest in untreated diabetic kidneys and was significantly lower in diabetic animals treated with Retatrutide (S vs. SR, p = 0.020) - the contrast in which diabetic status is held constant. Retatrutide alone did not alter HIF-1α relative to controls (R vs. C, δ = −0.28), indicating that the effect emerges under diabetic conditions rather than reflecting generalised suppression, and that it precedes clear structural recovery. Inflammatory cytokines show partial, power-limited signals: While IL-1β was significantly increased in the diabetic group, renal TNF-α in Retatrutide-treated diabetic animals was indistinguishable from that of controls (SR vs. C, g* = 0.03) despite a large standardised difference from untreated diabetic animals (S vs. SR, g* = 1.60), a contrast that did not reach significance under the conservative Games–Howell correction at the available sample sizes. This pattern is compatible with an anti-inflammatory trend that the present design was underpowered to confirm. Renal safety signal and translational implication: Retatrutide alone did not induce renal toxicity, as total cortical and medullary scores and subparameter scores in the Retatrutide-only group were comparable to controls, aligning with clinical data suggesting a favourable renal safety profile of incretin-based therapies and supporting further evaluation in chronic, T2DM-like models with longer treatment and functional readouts.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.